FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis

Oncogene, Published online: 19 July 2019; doi:10.1038/s41388-019-0893-4FABP7 is a key metabolic regulator in HER2+ breast cancer brain metastasis
Source: Oncogene - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Abstract Population-based study for predicting the prognosis for breast cancer liver metastasis (BCLM) is lacking at present. Therefore, the present study aimed to evaluate newly diagnosed BCLM patients of different tumor subtypes and assess potential prognostic factors for predicting the survival for BCLM patients. Specifically, data were collected from the Surveillance, Epidemiology and End Results program from 2010 to 2014, and were assessed, including the data of patients with BCLM. Differences in the overall survival (OS) among patients was compared via Kaplan-Meier analysis. Other prognostic factors of OS we...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: Mol Clin Oncol Source Type: research
Publication date: Available online 2 August 2019Source: European Journal of Surgical OncologyAuthor(s): Mariko Asaoka, Kazutaka Narui, Nobuyasu Suganuma, Takashi Chishima, Akimitsu Yamada, Sadatoshi Sugae, Saori Kawai, Natsuki Uenaka, Saeko Teraoka, Kana Miyahara, Takahiko Kawate, Eichi Sato, Toshitaka Nagao, Yuka Matsubara, Shipra Gandhi, Kazuaki Takabe, Takashi IshikawaAbstractIntroductionDespite the excellent prognosis associated with pathological complete response (pCR) to neoadjuvant chemotherapy (NAC), some patients still develop recurrence. Here, we investigated the outcomes of breast cancer patients with pCR, as we...
Source: European Journal of Surgical Oncology (EJSO) - Category: Surgery Source Type: research
Conditions:   Breast Cancer;   HER2-positive Breast Cancer;   Triple Negative Breast Cancer;   Hormone Receptor Positive Malignant Neoplasm of Breast;   Inflammatory Breast Cancer;   Metastatic Breast Cancer Intervention:   Device: MRI Sponsors:   Dana-Farber Cancer Institute;   Conquer Cancer Foundation Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Publication date: Available online 22 June 2019Source: Journal of Geriatric OncologyAuthor(s): Etienne Brain, Philippe Caillet, Nienke de Glas, Laura Biganzoli, Karis Cheng, Lissandra Dal Lago, Hans WildiersAbstractHER2-positive (HER2+) breast cancer (BC) affects older women nearly as frequently as younger ones. Many older patients have cardiovascular comorbidity and risk greater toxicity from therapy. Treatment therefore requires careful consideration, especially since trials include few patients over 65 and so provide limited guidance. A multidisciplinary task force of the International Society of Geriatric Oncology cond...
Source: Journal of Geriatric Oncology - Category: Cancer & Oncology Source Type: research
AbstractPurposeTo evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L.Materials and methodsWe conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L –T. Concomitant endocrine therapy, as well as brain metastasis and/or prior exposure to L, were allowed.ResultsOne hundred and fifteen patients from 14 institutions were included. The median age was 59.8  years. The median nu...
Source: Clinical and Translational Oncology - Category: Cancer & Oncology Source Type: research
JÁ, Ruiz-Borrego M, Guerrero-Zotano AL, Huerta M, Cotes-Sanchís A, Lao Romera J, Aguirre E, Cortés J, Llombart-Cussac A Abstract PURPOSE: To evaluate the efficacy and safety of lapatinib (L) and trastuzumab (T) combination in HER2-positive metastatic breast cancer (MBC) patients previously treated with T and/or L. MATERIALS AND METHODS: We conducted a retrospective, post-authorized, multicenter study including patients with HER2-positive MBC or locally advanced breast cancer (ABC) treated with the combination of L-T. Concomitant endocrine therapy, as well as brain metastasis and/or prior ...
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Tags: Clin Transl Oncol Source Type: research
AbstractLittle is known about the comparison of multiple-gated acquisition (MUGA) scanning with cardiovascular magnetic resonance (CMR) for serial monitoring of HER2+ breast cancer patients receiving trastuzumab. The association of cardiac biomarkers with CMR left ventricular (LV) function and volume is also not well studied. Our objectives were to compare CMR and MUGA for left ventricular ejection fraction (LVEF) assessment, and to examine the association between changes in brain natriuretic peptide (NT-BNP) and troponin-I and changes in CMR LV function and volume. This prospective longitudinal two-centre cohort study rec...
Source: The International Journal of Cardiovascular Imaging - Category: Radiology Source Type: research
Conclusion This study showed that elacridar influenced the pharmacokinetics of lapatinib. The inhibition of ABCB1 and ABCG2 transporters by elacridar substantially enhanced the penetration of lapatinib into the CSF and BT. The blocking of protein transporters could become indispensable in the treatment of patients with breast cancer and brain metastases.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research
ConclusionOur study suggests that the five hub genes (PHLPP1, UBC, ACACB, TGFB1, and ACTB) are associated with HER2 + BC with BM. The GSEA analysis revealed that the ribosomal pathway seems to play a very important role in the pathogenesis of HER2 + BC with BM.
Source: Pathology Research and Practice - Category: Pathology Source Type: research
More News: Brain | Brain Cancers | Breast Cancer | Cancer | Cancer & Oncology | HER2 | Neurology